| 摘要 | 第1-5页 |
| Abstract | 第5-7页 |
| CONTENTS | 第7-11页 |
| Table of Abbreviations | 第11-14页 |
| List of Figures | 第14-15页 |
| List of Tables | 第15-16页 |
| 1 INTRODUCTION | 第16-28页 |
| ·Ginkgo biloba | 第16-17页 |
| ·Extract Ginkgo biloba and its constituents | 第17-19页 |
| ·The terpene trilactones ginkgolide A, B and bilobalide | 第19-20页 |
| ·Myocardial infarction | 第20-22页 |
| ·PAF and PAFR | 第22-24页 |
| ·EGb761 and endothelial cells/angiogenesis | 第24页 |
| ·Angiogenesis | 第24-25页 |
| ·Coronary angiography by synchrotron radiation | 第25-26页 |
| ·Aim of the study | 第26-28页 |
| 2 MATERIALS AND METHODS | 第28-48页 |
| ·Materials | 第28-32页 |
| ·Ginkgolide A, B and bilobalide | 第28页 |
| ·Aspirin | 第28页 |
| ·Erythropoietin | 第28-29页 |
| ·Solutions and Laboratory equipment | 第29-30页 |
| ·Cell culture solutions | 第30-31页 |
| ·Animals | 第31-32页 |
| ·Methods | 第32-48页 |
| ·NC culture | 第32页 |
| ·HUVEC culture | 第32页 |
| ·Hypoxia | 第32-33页 |
| ·MTT assay | 第33页 |
| ·Lactate dehydrogenase activity (LDH) assay | 第33-34页 |
| ·Hoechst staining | 第34-36页 |
| ·Immunofluorescence | 第36页 |
| ·Flow cytometry | 第36-38页 |
| ·Myocardial Infarction model | 第38页 |
| ·Trial 1:Acute myocardial infarction | 第38-39页 |
| ·Trial 2:heart failure | 第39页 |
| ·Infarct size | 第39-40页 |
| ·Lung-to-body weight ratio | 第40页 |
| ·Coronary angiography | 第40-42页 |
| ·Doppler Echocardiography | 第42页 |
| ·Protein quantification by Bicinchoninacid (BCA) | 第42-43页 |
| ·Phospholipase A2 activity assay | 第43页 |
| ·RNA isolation and RT-PCR | 第43-44页 |
| ·Western blotting | 第44-47页 |
| ·In Vitro Sample Preparation | 第45页 |
| ·In Vivo Sample Preparation | 第45页 |
| ·Protein separation | 第45-46页 |
| ·Transfer | 第46-47页 |
| ·Protein staining | 第47页 |
| ·Statistical analysis | 第47-48页 |
| 3 RESULTS | 第48-74页 |
| ·In vitro:Cell culture experiments | 第48-66页 |
| ·MTT | 第48-51页 |
| ·NC | 第48-50页 |
| ·HUVEC | 第50-51页 |
| ·LDH | 第51页 |
| ·PLA2 activity | 第51-52页 |
| ·Hoechst staining | 第52-56页 |
| ·NC | 第52-54页 |
| ·HUVEC | 第54-56页 |
| ·Apoptosis detection by FACS HUVEC | 第56-58页 |
| ·Apoptosis markers bax, bcl-2 and apaf-1 mRNA expression in NC and endothelial cells (RT-PCR) | 第58-61页 |
| ·NC | 第58-59页 |
| ·HUVEC | 第59-61页 |
| ·Western blotting of apoptosis marker proteins bax and bcl-2 | 第61-62页 |
| ·Immunofluorescence microscopy of PAFR on NC | 第62-64页 |
| ·PAFR and PAFAH mRNA expression (RT-PCR) in NC | 第64页 |
| ·Western blotting of PAFR and PAFAH in NC | 第64-66页 |
| ·In vivo:Myocardial Infarction model | 第66-74页 |
| ·Trial 1:Protective effects of bilobalide during myocardial infarction | 第66-68页 |
| ·Trial 1:Western blotting of apoptosis marker proteins bax and bcl-2 in myocardial tissue | 第68-69页 |
| ·Trial 1:Western blotting of PAFR and PAFAH in myocardial tissue | 第69页 |
| ·Trial 2:Curative effects of bilobalide in heart failure following myocardial infarction | 第69-71页 |
| ·Trial 2:Coronary Angiography using synchrotron radiation | 第71-72页 |
| ·Trial 2:Doppler Echocardiography Studies | 第72-74页 |
| 4 DISCUSSION | 第74-84页 |
| ·In vitro | 第74-79页 |
| ·Bilobalide and ginkgolide A improve viability of NC during hypoxia | 第75页 |
| ·Bilobalide improves viability of endothelial cells during hypoxia | 第75-76页 |
| ·Bilobalide reduces LDH leakage during hypoxia | 第76页 |
| ·Bilobalide reduces PLA2 activity during hypoxia | 第76页 |
| ·Bilobalide doesn't affect apoptosis marker proteins in NC during hypoxia | 第76-77页 |
| ·Bilobalide inhibits apoptosis in endothelial cells during hypoxia | 第77页 |
| ·NC express PAFR, while fibroblasts do not | 第77页 |
| ·Bilobalide downregulates PAFR expression in NC during hypoxia | 第77-78页 |
| ·Bilobalide upregulates PAF-AH expression in NC during hypoxia | 第78-79页 |
| ·In vivo | 第79-84页 |
| ·Bilobalide doesn't affect mortality after myocardial infarction | 第79页 |
| ·Ginkgolide A enhances myocardial infarction | 第79-80页 |
| ·PAFR is upregulated in the infarcted left ventricle and bilobalide downregulates PAFR expression in the infarcted left ventricle | 第80页 |
| ·PAF-AH is downregulated in the in the infarcted left ventricle and bilobalide upregulates PAF-AH after myocardial infarction | 第80页 |
| ·Bilobalide doesn't affect mortality in heart failure after myocardial infarction | 第80-81页 |
| ·Bilobalide doesn't affect functional parameters of the left ventricle in heart failure | 第81页 |
| ·Coronary angiography using synchrotron radiation is an interesting tool to observe angiogenesis in vivo | 第81-84页 |
| 5 CONCLUSION | 第84-86页 |
| REFERENCES | 第86-96页 |
| APPENDIX | 第96-97页 |
| Curriculum vitae | 第97-98页 |
| Acknowledgments | 第98-100页 |
